by John A. Jenkins | Sep 3, 2026 | FDA, FOIA
FOIAengine: Newly Remade Advisory Committee Green Lights Six Compounds, Despite the Applications Being Pulled Bobby Harshbarger is a Tennessee state senator and pharmacist of noteworthy lineage, with an interesting backstory. Both of his parents are...
by Randy Miller | Aug 20, 2026 | FDA, FOIA, News Media, Politics
FOIAengine: Twenty-One Requests from News Media, Non-Profits and Companies The nationwide outbreak of cyclospora infections this summer prompted a steady stream of national and local news articles, along with 21 Freedom of Information Act requests to the Food and Drug...
by John A. Jenkins | Aug 12, 2026 | FOIA, SEC
As the artificial-intelligence arms race heats up, Meta and Google have turned to Wall Street for help paying the multi-billion-dollar tab. Amid data-center financing terms that even Google’s auditor calls questionable, a Washington securities lawyer whose clients...
by John A. Jenkins | Aug 5, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Stock Market
FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
by John A. Jenkins | Jul 30, 2026 | FDA, FOIA, News Media, Pharmaceuticals, Politics
FOIAengine: Multiple News Outlets Sought Details on “Compassionate Use” Within days of a Stat News report describing a highly unusual government decision to grant a 79-year-old patient early access to Eli Lilly’s experimental obesity drug retatrutide, some of the...
by John A. Jenkins | Jul 16, 2026 | FOIA, Politics
FOIAengine: How the GOP’s Senate Campaign Committee Plays the Oppo Game While national reporters were examining Graham Platner’s turbulent personal life, Republican opposition researchers were quietly investigating an entirely different chapter of the Maine Senate...
